article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. WuXi STA has 12 sites across the US, Europe and Asia. This campus is only possible because of Delaware’s world-class, innovative workforce.

article thumbnail

Novo Nordisk to expand French production facilities

European Pharmaceutical Review

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. Recent European manufacturing investments Earlier this month, Novo Nordisk announced that it was planning another manufacturing facility expansion, this time at its site in Kalundborg, Denmark. Construction has already begun.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Industry welcomes boost to health research in UK budget

pharmaphorum

The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous contribution made by the life sciences sector in helping to limit the impact of the pandemic through the rapid development of diagnostics, drugs and vaccines.

article thumbnail

16th edition of CPHI & PMEC India Expo to be held from November 28-30, 2023, at India Expo Centre, Greater Noida

Express Pharma

The expo enjoys support from key industry associations such as Bulk Drug Manufacturing Association (BDMA), Federation of Pharma Entrepreneurs (FOPE), Karnataka Drugs and Pharmaceuticals Manufacturers’ Association (KDPMA), Organisation of Pharmaceutical Producers of India (OPPI), and Pharmaceutical Export Promotion Council (Pharmexcil).

Packaging 105
article thumbnail

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

FDA Law Blog: Biosimilars

The court did not make much of Plaintiff’s argument that a manufacturer cannot terminate its participation in Medicare for close to two years, see Motion at 8; Complaint at 27-28, potentially dismissing it as a mere administrative matter. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing.